Savion Gropper
Boehringer Ingelheim (Germany)(DE)
Publications by Year
Research Areas
Venous Thromboembolism Diagnosis and Management, Blood Coagulation and Thrombosis Mechanisms, Cardiac Arrhythmias and Treatments, Atrial Fibrillation Management and Outcomes, Dermatology and Skin Diseases
Most-Cited Works
- → Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation(2017)1,335 cited
- → Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority trial(2020)137 cited
- → Traditional and New Composite Endpoints in Heart Failure Clinical Trials: Facilitating Comprehensive Efficacy Assessments and Improving Trial Efficiency(2016)93 cited
- → Safety of dabigatran etexilate for the secondary prevention of venous thromboembolism in children(2019)90 cited
- → Design and Rationale of the RE‐DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fibrillation Who Have Undergone Percutaneous Coronary Intervention With Stenting(2016)70 cited
- → Ozenoxacin 1% Cream in the Treatment of Impetigo: A Multicenter, Randomized, Placebo- and Retapamulin-Controlled Clinical Trial(2014)43 cited
- → Phase IIa study of dabigatran etexilate in children with venous thrombosis: pharmacokinetics, safety, and tolerability(2017)34 cited
- → Challenges and Opportunities in IBD Clinical Trial Design(2021)30 cited
- → Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Dabigatran Etexilate Oral Liquid Formulation in Infants with Venous Thromboembolism(2017)29 cited
- → Safety and tolerability of spesolimab in patients with ulcerative colitis(2022)27 cited